BUDEALFA (Budesonide) is a second-generation synthetic glucocorticoid, effective in treating patients with IgAN at high risk of progression in terms of reducing proteinuria, hematuria and preserving renal function. It is a gastro-resistant, pH-modified formulation with a maximum release of active compound in the distal ileum and proximal colon. Additionally, it has an extensive first-pass metabolism and induces only mild and transient reductions in plasma cortisol levels, thus sparing steroid-related side effects.

Therapy Area: Renal Medicine
Form: Tablet
Packaging: 1x10 Tablets


Budesonide 9mg Controlled Release Tablet


In patients with IgA nephropathy, mucosal B lymphocytes located in Peyer’s patches produce IgA1 that is galactose deficient (GdIgA1), which forms large immune complexes with IgG antibodies in the circulation. As these immune complexes accumulate in the mesangium, inflammatory and fibrotic cascades develop, causing progressive kidney damage. Budesonide acts directly at the site of action. It shows immunosuppressive action by reducing the formation of IgA1 antibodies from the Peyer’s patches of the intestine. It also provides anti-inflammatory action by reducing inflammation in the glomerulus of the kidney. The COLOMAT technology in Budealfa provides gastro-resistant, controlled-release formulation with maximum release of active compound in the intestine. It undergoes high first-pass elimination by the liver so that systemic levels are minimal after oral administration, thus sparing the steroid-related side effects.


  • IgA Nephropathy (IgAN)
  • Proteinuria in IgA Nephropathy
  • Hematuria in IgA Nephropathy


Initial Dose: Twice daily or as directed by the physician.


This information is for registered medical practitioner only. Anyone other than medical practitioner should consult medical practitioner before using this product.

Enquire About BUDEALFA

Fill the form below and we will get in touch with you

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.